You're seeing the small picture.
PIP.-Theraclone is to receive $632 million from Pfizer for a collaborative effort of I-STAR. You can figure out what that means to valuation.
PIP will receive a continual revenue stream from SIGA.
Theraclone is backed by 8 big investors that will cause the stock to move multiples higher.
Theraclone is working on HIV, 2 influenza products, and 5 other compounds.
PIP has a 2 year valuation of $8-18.
Do some research. It's all good for PIP.